Literature DB >> 31477856

Transition probabilities for clinical trials: investigating individual diseases.

Kathleen L Miller, Dina Rabinovitz, Kirk W Kerr.   

Abstract

Entities:  

Keywords:  Drug discovery

Year:  2019        PMID： 31477856     DOI： 10.1038/d41573-019-00124-6

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.

Authors:  Kathleen L Miller; Lewis J Fermaglich; Janet Maynard
Journal:  Orphanet J Rare Dis       Date:  2021-06-09       Impact factor: 4.123

2.  FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.

Authors:  Kathleen L Miller; Christine Mueller; Gumei Liu; Katherine I Miller Needleman; Janet Maynard
Journal:  Orphanet J Rare Dis       Date:  2020-09-03       Impact factor: 4.123
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.